Last Updated on December 16, 2024 by The Health Master
NPPA
The National Pharmaceutical Pricing Authority (NPPA) has taken a crucial step to ensure the continued availability of essential drugs in India.
In a recent statement to the Lok Sabha, Minister of State for Chemicals and Fertilizers, Anupriya Patel, revealed that the NPPA approved a price increase for 11 drugs of 8 essential drugs.
Responding to Industry Concerns
This decision comes after the NPPA received applications from various pharmaceutical companies and industry associations requesting price revisions for a total of 77 drugs
These requests stemmed from concerns about the viability of maintaining current pricing due to factors such as:
- Increased Production Costs: The cost of manufacturing these drugs has risen.
- API Price Fluctuations: The price of Active Pharmaceutical Ingredients (APIs), the essential components of drugs, has experienced an upward trend.
- Currency Exchange Rates: Changes in foreign exchange rates have impacted the cost of imported materials.
- Discontinued drugs: Certain drugs were at risk of being discontinued due to financial constraints.
Balancing Availability and Affordability
The NPPA, after meticulous examination, approved price increases for 11 drugs across 8 drugs, prioritizing continued market availability.
This move aims to prevent a scenario where patients are forced to switch to more expensive alternatives due to a lack of essential drugs.
Focus on Essential Treatments
The price-adjusted drugs are primarily used as first-line treatments for critical health conditions like:
- Asthma
- Glaucoma
- Thalassemia
- Tuberculosis
- Mental Health Disorders
The low-cost nature of these drugs makes them crucial components of public health programs across India.
Minimal Impact on Patients
According to a senior government official, the price revisions are unlikely to significantly impact patients.
Many of these drugs are readily available for free in government hospitals and through public health initiatives focused on providing free essential treatments.
A History of Intervention
This is not the first time the NPPA has intervened to ensure the availability of essential drugs.
In 2019 and 2021, the authority used its powers to approve price increases for 21 and 9 drugs, respectively, to maintain access to crucial drugs.
This action by the NPPA demonstrates the government’s commitment to ensuring access to essential drugs for all citizens of India.
-
Which drugs are affected by the price increase?
The price increase applies to 11 drugs across 8 essential drugs, including Benzyl Penicillin injection, Atropine injection, Streptomycin injection powder, Salbutamol tablets and solution, Pilocarpine eye drops, Cefadroxil tablets, Desferrioxamine injection, and Lithium tablets.
-
Will this impact the affordability of these drugs?
Many of these drugs are readily available for free in government hospitals and public health programs, so the price increase is unlikely to significantly impact individual patient affordability.
-
What factors led to the price increase?
The price increase was a response to rising production costs, API price fluctuations, currency exchange rates, and the potential discontinuation of certain drug drugs due to financial constraints.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
Latest on National Pharmaceutical Pricing Authority (NPPA)
Latest notifications – DPCO / NPPA
NPPA updated price lists: Download
Latest Notifications: EC Act (Essential Commodities Act)
NPPA’s ceiling price for Methylprednisolone Upheld
Ceiling Price for Acyclovir 800 mg Tablets upheld
NPPA recalculates Ceiling Price of Atorvastatin 10mg
NPPA Revises Ceiling Prices of these Key Drugs
Four arrested for supplying Spurious Drugs to Maharashtra Hospital
Key Notes on Revised Schedule M: Point No. 4 – Sanitation and Hygiene
Wearable Medical device: The Future of Heart Health Monitoring
Blast at Hyderabad pharma unit: NGT issues notice
Piramal Pharma Pays USD 407,400 to Resolve Legal Battle
India Boosts Pharma Manufacturing with Rs 15,000 Crore PLI Scheme
Key Notes on Revised Schedule M: Point No. 3 – Good Manufacturing Practice (GMP)
AIDCOC Seeks Revocation and Investigation on Karnataka Drug Controller Suspension
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
